OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) major shareholder Jennifer Pritzker sold 18,000 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $24.28, for a total transaction of $437,040.00. Following the completion of the sale, the insider owned 6,863,464 shares of the company’s stock, valued at $166,644,905.92. The trade was a 0.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
OrthoPediatrics Stock Performance
KIDS stock traded down $0.47 during mid-day trading on Wednesday, reaching $24.03. 169,608 shares of the stock traded hands, compared to its average volume of 171,545. The business has a 50-day moving average of $21.11 and a two-hundred day moving average of $18.53. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The firm has a market capitalization of $627.42 million, a PE ratio of -14.30 and a beta of 0.98. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.
OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. The firm had revenue of $70.51 million for the quarter, compared to analyst estimates of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. As a group, equities analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Ratings Changes
KIDS has been the topic of a number of recent research reports. Weiss Ratings upgraded shares of OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Needham & Company LLC upped their target price on shares of OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. TD Cowen reissued a “buy” rating on shares of OrthoPediatrics in a research note on Monday, June 15th. BTIG Research increased their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, August 20th. Finally, Truist Financial set a $22.00 target price on OrthoPediatrics in a report on Wednesday, August 5th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.44.
Get Our Latest Stock Report on KIDS
OrthoPediatrics Company Profile
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Read More
- Five stocks we like better than OrthoPediatrics
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for OrthoPediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OrthoPediatrics and related companies with MarketBeat.com's FREE daily email newsletter.
